Immunocore Holdings plc

Abingdon, Oxfordshire, X0 · Founded 2021 · CIK 0001671927 · Biotech · Private

Immunomodulating medicines that redirect T cells to target disease

immunocore.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$140M
1 Form D · Jul 2022
50 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$139,999,988
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2795Octant Bio——
2796Enable Therapeutics LLC——
2797RGENE, INC.——
2798Immunocore Holdings plc—$140M
2799Black Diamond Therapeutics—$140M
2800VYNE Therapeutics Inc.—$139M
2801Silverback Therapeutics—$139M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 11 related persons
  • John BellDirector
  • David BermanExecutive Officer
  • Travis CoyDirector
  • Brian Di DonatoExecutive Officer
  • Roy HerbstDirector
  • Bahija JallalDirector · Executive Officer
  • Siddharth KaulDirector
  • Robert PerezDirector
  • Kristine PetersonDirector
  • Peter RatcliffeDirector
  • Tina St. LegerExecutive Officer

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.